Global threat of carbapenem-resistant gram-negative bacteria
Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …
Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
Current update on intrinsic and acquired colistin resistance mechanisms in bacteria
Colistin regained global interest as a consequence of the rising prevalence of multidrug-
resistant Gram-negative Enterobacteriaceae. In parallel, colistin-resistant bacteria emerged …
resistant Gram-negative Enterobacteriaceae. In parallel, colistin-resistant bacteria emerged …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae
Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …
challenging, and some of the few active drugs are not available in many countries. For …
RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with …
J Motsch, C Murta de Oliveira, V Stus… - Clinical Infectious …, 2020 - academic.oup.com
Background The β-lactamase inhibitor relebactam can restore imipenem activity against
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …
Colistin update on its mechanism of action and resistance, present and future challenges
FF Andrade, D Silva, A Rodrigues, C Pina-Vaz - Microorganisms, 2020 - mdpi.com
Colistin has been extensively used since the middle of the last century in animals,
particularly in swine, for the control of enteric infections. Colistin is presently considered the …
particularly in swine, for the control of enteric infections. Colistin is presently considered the …
Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes
Polymyxins are well-established antibiotics that have recently regained significant interest
as a consequence of the increasing incidence of infections due to multidrug-resistant Gram …
as a consequence of the increasing incidence of infections due to multidrug-resistant Gram …
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised …
Background Colistin–carbapenem combinations are synergistic in vitro against carbapenem-
resistant Gram-negative bacteria. We aimed to test whether combination therapy improves …
resistant Gram-negative bacteria. We aimed to test whether combination therapy improves …